- Piramal Pharma Solutions and NewAmsterdam Pharma have opened a dedicated oral solid dosage (OSD) suite at the Sellersville, Pennsylvania site to support fixed dose combination (FDC) production.
- The multi-million-dollar investment will improve operational efficiency, create more than 20 jobs over five years, and enable commercial-scale production of the FDC if approved.
Piramal Pharma Solutions, a global CDMO, and NewAmsterdam Pharma have launched a dedicated OSD form suite at the Sellersville, Pennsylvania, facility. The suite will support the production of NewAmsterdam Pharma’s investigational fixed-dose combination therapy of obicetrapib and ezetimibe, a non-statin cholesterol medication intended to reduce LDL-C.
The multi-million-dollar investment includes reconfiguring existing space and upgrading equipment for turnkey, multi-layer tablet production, covering granulation, compression, tableting, and coating. This expansion is designed exclusively for FDC products, enhancing both production capacity and operational efficiency.
The collaboration extends beyond Sellersville. Piramal’s Ahmedabad PPDS site in India contributed to product development, while the Pithampur site provides dual sourcing support, demonstrating the advantages of Piramal’s integrated contract manufacturing approach.
Peter DeYoung, CEO of Piramal Global Pharma, stated: “We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite. This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too.”
The investment is also expected to benefit the local economy by creating more than 20 new jobs over the next five years. According to Douglas Kling, COO of NewAmsterdam Pharma, “By investing in Piramal Pharma Solutions’ Sellersville facility, we are enabling the manufacture of FDC with exceptional precision and efficiency to meet the future commercial demand.”
